Heterogeneity origins and maintenance.

Slides:



Advertisements
Similar presentations
Metastasis. Mechanisms of Invasion and Metastasis.
Advertisements

PROLIFERAZIONE CELLULARE E RESISTENZA AI FARMACI.
Robert Farley University of Rhode Island Department of Biomedical Engineering.
Dental Microbiology #211 IMMUNOLOGY 2006 Lecture 2 The Lymphocytes.
Tumor Cells and the Onset of Cancer
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
A schematic comparison is shown of the highly coordinated and quantitatively regulated hierarchy of normal tissue populations in which cell turnover is.
Review: Cancer Modeling
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
The process of (micro)evolution
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Kusumawadee Utispan, Sittichai Koontongkaew 
Colorectal Cancer Stem Cells: From the Crypt to the Clinic
IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.
Figure 3 Monitoring clonal evolution using liquid biopsies
Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.
Cancer stem cells and their application into targeted therapy for cancer Mol. Bio. Lab Park Ji Won Supervisor ; Dae Youn Hwang.
Figure 1 Treatment-induced resistance and evolution to lineage crisis
Colorectal Cancer Stem Cells: From the Crypt to the Clinic
Telomeres and Cancer: From Crisis to Stability to Crisis to Stability
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
The AML Salad Bowl Cancer Cell
Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on.
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.
Figure 5 The mechanism underlying epithelial-to-mesenchymal
Corrupted tensional homeostasis accompanies tumor progression.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Volume 22, Issue 6, Pages (December 2012)
Giulio Francia, Urban Emmenegger, Robert S. Kerbel  Cancer Cell 
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
Stem Cell Heterogeneity and Plasticity in Epithelia
Michael D. Brooks, Monika L. Burness, Max S. Wicha  Cell Stem Cell 
Evolution of the Cancer Stem Cell Model
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
Juan R. Cubillos-Ruiz, Sarah E. Bettigole, Laurie H. Glimcher  Cell 
Tumor-Associated Macrophages: From Mechanisms to Therapy
Stem Cells and Cancer: Two Faces of Eve
From Cancer Stem Cells to Tumor Maintenance in Melanoma
Elanor N. Wainwright, Paola Scaffidi  Trends in Cancer 
Drugging Drug Resistance
Cancer Stem Cells: Current Status and Evolving Complexities
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Nicholas McGranahan, Charles Swanton  Cancer Cell 
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Adaptive NK cells resist immunosuppression in the tumor microenvironment. Adaptive NK cells resist immunosuppression in the tumor microenvironment. FACS-sorted.
Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.
Hariharan Easwaran, Hsing-Chen Tsai, Stephen B. Baylin  Molecular Cell 
Protein expression profile in a dasatinib-resistant cell line.
Attacking Cancer at Its Root
In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.
Mechanical forces can promote tumor aggression.
Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.
Biomechanical force may promote tumor progression by establishing an aggressive tumor cell hierarchy. Biomechanical force may promote tumor progression.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
GR CAFs modulate the EGFR-TKI response in cocultured tumor cells.
Simplified BRAF signaling network.
A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.
Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.
MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.
p53 loss affects several steps of the metastatic process.
Frequent coamplification of RTKs in MET-amplified EGC
Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.
Immune escape mechanisms in cancer.
Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.
Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.
The AML Salad Bowl Cancer Cell
Presentation transcript:

Heterogeneity origins and maintenance. Heterogeneity origins and maintenance. A, according to clonal evolution, heterogeneity is caused by the acquisition of mutations and expansion. Upon a selective pressure, such as drug treatment, more adapted clones survive and, through consequent mutations, give rise again to a heterogeneous population. B, the CSC model postulates that only CSCs are able to divide indefinitely, giving rise to cells that will differentiate heterogeneously. CSCs can also acquire mutations and generate a heterogeneous CSC population. CSCs are considered to be drug resistant, such that surviving cells serve as a reservoir for tumor relapse. C, whether heterogeneity arises by clonal evolution, CSCs, or CSCs undergoing clonal evolution, its maintenance requires interactions between CSCs and/or tumor cells and their microenvironment and between different CSCs and/or tumor cell clones. Those interactions can drive an increase in tumor growth, drug resistance, immune suppression, angiogenesis, invasion, or even CSC renewal. D, ΔEGFR cells secrete factors, such as interleukin (IL)-6 and leukemia-inhibitory factor (LIF), which, through a paracrine mechanism, activate wtEGFR cells, resulting in a significant tumor growth enhancement as compared with a wtEGFR homogeneous tumor. Rudy Bonavia et al. Cancer Res 2011;71:4055-4060 ©2011 by American Association for Cancer Research